



## **Curetis to Publish its Annual Results 2015**

**on April 12, 2016**

***- Company to host earnings conference call and webcast***

**Amsterdam, the Netherlands and Holzgerlingen, Germany, March 24, 2016** -- Curetis N.V. (the "**Company**") and, together with Curetis GmbH, "**Curetis**"), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2015 financial results on April 12, 2016. In addition, the Company will host a public earnings conference call and webcast on April 12, 2016, at 03:00pm CET / 09:00am EST to present the financial results of 2015, highlight the most important events and provide an outlook for 2016.

The conference call will be supplemented by a presentation which can be accessed during the call at <http://www.curetis.com/en/investors/financial-reports-and-conferences/financial-reports.html>

The live webcast and a replay will be available at <http://curetis120416-live.audio-webcast.com>

To access the call, please dial the following numbers using the passcode 93120684#

Germany: +49 69 222229043

UK: +44 20 30092452

US: +1 855 4027766

For further international dial-in numbers, please open the following link:

[http://events.arkadin.com/ev/docs/International%20Access%20Numbers\\_%20UKFELBRI1SU7.pdf](http://events.arkadin.com/ev/docs/International%20Access%20Numbers_%20UKFELBRI1SU7.pdf)

The full annual financial report 2015 will be available as of April 12, 2016, at <http://www.curetis.com/en/investors/financial-reports-and-conferences/financial-reports.html>

### **Disclaimer**

**CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.**

###

## **About Curetis**

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

**For further information, please visit [www.curetis.com](http://www.curetis.com).**

## **Legal Disclaimer**

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment in the commercial register at district court Stuttgart on March 15, 2016 Curetis plc (AG) changed its legal form into Curetis Ltd. (GmbH).

## **Contact details**

Curetis  
Max-Eyth-Str. 42  
71088 Holzgerlingen, Germany  
Tel. +49 7031 49195-10  
[pr@curetis.com](mailto:pr@curetis.com) or [ir@curetis.com](mailto:ir@curetis.com)  
[www.curetis.com](http://www.curetis.com) - [www.unyvero.com](http://www.unyvero.com)

## **International Media & Investor Inquiries**

akampion  
Dr. Ludger Wess / Ines-Regina Buth  
Managing Partners  
info@akampion.com  
Tel. +49 40 88 16 59 64  
Tel. +49 30 23 63 27 68

**U.S. Media & Investor Inquiries**

The Ruth Group  
Lee Roth  
lroth@theruthgroup.com  
Tel. +1 646 536 7012